New Treatment Option for Relapsing Multiple Sclerosis

Thomas Leist, MD, PhD, director of the Comprehensive Multiple Sclerosis Center at Jefferson University Hospitals, reviews data from a subgroup analysis that suggests efficacy for cladribine even in patients in the earliest stages of disease.

Stephen Krieger, MD, discusses the recent approval of oral cladribine and where it fits in an increasingly crowded landscape of disease-modifying therapies for multiple sclerosis.

Tim West, MD, discusses which patients with MS derive the best benefit from cladribine, as well as some of its advantages in dosing.
SAP Partner Banner